Two Speculative Healthcare Stocks to Watch This Week |
![]() |
![]() |
By David Ibrahim |
Monday, 12 November 2012 08:12 |
In fact, accumulation of MRIC shares has been on a very steady rise since July as speculators have been betting that the company’s disruptive technology—which revolutionizes the way minimally-invasive brain surgeries are performed—is set to increase market share with sales to hospitals gaining traction at a higher than anticipated pace. During the last few sessions, the stock has become heavily shorted without any fundamental reason and despite recent insider buying . If good news flow continues to flow, these shorts could be squeezed pretty tightly and share price could start to push higher. Again, speculators are betting that the company will report good news/guidance this week—which will cause a healthy short-squeeze. Here is a look at the MRIC chart: The second stock is Tekmira Pharmaceuticals (NASDAQ: TKMR). This one spiked to a 52-week high last Thursday and finished the session with trading volume that surpassed their volume from the previous three days. We’re looking for confirmation that the positive trend may continue after some profit-taking on Friday. There was a pull-back from overbought levels after stock prices hit a new high of 5.44. Speculators are placing their bets on the outcome of this week’s upcoming trial against Alnylam Pharmaceuticals (NASDAQ: ALNY) in which TKMR alleges their trade secrets regarding lipid particles for effective delivery of therapeutic siRNA were misappropriated. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |